Know Cancer

or
forgot password

A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens


Phase 2
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens

Inclusion Criteria


Inclusion Criteria

- Stage IIIB or IV non-small cell lung cancer.

- Recurrent tumor following treatment with paclitaxel or docetaxel.

- Able to tolerate normal activities of daily living.

- Adequate bone marrow, kidney and liver function.

Exclusion Criteria

- Pregnant or breast feeding.

- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.

- CNS metastasis.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate in subjects with NSCLC

Outcome Time Frame:

1 year

Principal Investigator

Helen Eliopoulos, MD

Investigator Role:

Study Director

Investigator Affiliation:

Abbott

Authority:

United States: Food and Drug Administration

Study ID:

M02-448

NCT ID:

NCT00073151

Start Date:

September 2003

Completion Date:

January 2006

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Washington University School of Medicine Saint Louis, Missouri  63110
University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin  53792
Albany Regional Cancer Center Albany, New York  12208
Cancer Centers of the Carolinas Greenville, South Carolina  29605
Cancer Care Northwest Spokane, Washington  99202
Cancer Care Associates Tulsa, Oklahoma  74136
Northwest Cancer Specialists Vancouver, Washington  98664
West Cancer Clinic Memphis, Tennessee  38120
University of Chicago Medical Center Chicago, Illinois  60637
University of Maryland Greenbaum Cancer Center Baltimore, Maryland  21201
Oncology Hematology Group of South Florida Miami, Florida  33176
Texas Oncology Dallas, Texas  
Florida Cancer Institute New Port Richey, Florida  34652
Oncology & Hematology Associates of Kansas City, PA Kansas City, Missouri  64111
Raleigh Hematology Oncology Cary, North Carolina  
Dayton Oncology and Hematology Kettering, Ohio